← FDA DRUG APPROVALS

FDA ANDA · ANDA086179

CARISOPRODOL

Sponsor: WATSON LABS TEVA

APPLICATION
ANDA086179
TYPE
ANDA
ORIGINAL APPROVAL
1979-06-12
LATEST ACTION
1997-07-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CARISOPRODOLDiscontinued
CARISOPRODOL 350MG · TABLET · ORAL

Approval history

1997-07-07Manufacturing (CMC) · Supplement 34AP
1997-07-07Manufacturing (CMC) · Supplement 35AP
1997-07-07Manufacturing (CMC) · Supplement 33AP
1996-06-06Manufacturing (CMC) · Supplement 32AP
1996-06-06Manufacturing (CMC) · Supplement 31AP
1994-02-02Manufacturing (CMC) · Supplement 28AP
1994-02-02Manufacturing (CMC) · Supplement 29AP
1992-05-01Labeling · Supplement 30AP
1988-08-22Manufacturing (CMC) · Supplement 26AP
1988-08-22Manufacturing (CMC) · Supplement 24AP
1988-08-22Manufacturing (CMC) · Supplement 27AP
1988-08-22Manufacturing (CMC) · Supplement 25AP
1987-08-24Manufacturing (CMC) · Supplement 21AP
1987-08-24Manufacturing (CMC) · Supplement 18AP
1987-08-24Manufacturing (CMC) · Supplement 22AP
1987-04-16Manufacturing (CMC) · Supplement 20AP
1986-09-22Manufacturing (CMC) · Supplement 9AP
1986-09-22Manufacturing (CMC) · Supplement 8AP
1984-10-10Manufacturing (CMC) · Supplement 15AP
1979-06-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →